Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed

Mar 26 2020

• By Joseph Haas

3d illustration of nerve cells, concept for Neurological Diseases, tumors and brain surgery. — BMS says Zeposia offers a new treatment option for relapsing MS patients

Related Content

Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV

Mar 23 2020

EU Approval Decision Delay For BMS’s Ozanimod

Mar 06 2020

FDA Backs Novartis MS Pill Mayzent With Broad Label

Mar 27 2019

Novartis Makes Mayzent Case With More MS Data

Sep 12 2019

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Top US Generics Players Thwarted On August At-Risk Launch Of Fingolimod

Jun 27 2019

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Novartis AG

Biogen, Inc.

Johnson & Johnson

Additional Topics

Approvals Business Strategies Commercial BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window